The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health. TEMPOL can limit SARS-CoV-2 infection by impairing the activity of a viral enzyme called RNA replicase. The work was led by researchers at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The study appears in Science.
NIH researchers identify potential new antiviral drug for COVID-19
June 3, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022